ADMA Biologics ADMA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 57.4%+5.9pp | 51.5%+17.0pp | 34.4%+11.6pp | 22.9%+21.4pp | |
| Operating margin | 37.5%+4.9pp | 32.6%+24.2pp | 8.4%+33.9pp | -25.5%+46.6pp | |
| Net margin | 28.8%-17.6pp | 46.4%+57.3pp | -10.9%+31.8pp | -42.8%+45.7pp | |
| Returns | |||||
| Return on equity | 35.6%-46.1pp | 81.6%+101pp | -19.7%+25.3pp | -45%+17.5pp | |
| Return on invested capital | 38.6%-27.1pp | 65.8%+40.6pp | 25.2%+70.1pp | -44.9%+6.2pp | |
| Efficiency | |||||
| Asset turnover | 0.9×-0.1× | 1×+0.3× | 0.8×+0.3× | 0.5×+0.2× | |
| Liquidity | |||||
| Current ratio | 6.7×+0.7× | 6×+0.8× | 5.2×-1.7× | 6.9×0.0× | |
| Leverage | |||||
| Debt-to-equity | 0.2×-0.1× | 0.2×+0.2× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -0×+0.1× | -0.1×+1.2× | -1.4×— | —— | |
| Per Share | |||||
| Book value per share | $1.95+35.9% | $1.43+138% | $0.60-21.4% | $0.77-24.1% | |
| Valuation | |||||
| Market capitalization | $4.34B+7.1% | $4.05B+297% | $1.02B+19.2% | $857.1M+210% | |
| Price / earnings | 29.5×+9.0× | 20.5×— | —— | —— | |
| Price / sales | 8.5×-1.0× | 9.5×+5.6× | 4×-1.6× | 5.6×+2.2× | |
| Price / book | 9.1×-2.5× | 11.6×+4.1× | 7.6×+1.9× | 5.6×+3.7× | |
| EV / EBITDA | 21.7×-5.8× | 27.5×-6.1× | 33.6×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ADMA Biologics's profit margins?
- ADMA Biologics (ADMA) runs a 61.3% gross margin and a 42.1% operating margin, with a 32.4% net margin.
- Where do ADMA Biologics's ratios come from?
- Every ratio is computed from ADMA Biologics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
